Search results for: Alain H. Rook

Items from 1 to 20 out of 64 results

article

Management of relapsed cutaneous T‐Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case

David M. Weiner, Daniel J. Lewis, Natalie G. Spaccarelli, Rachael A. Clark, more

Dermatologic Therapy > 35 > 7 > n/a - n/a

Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative treatment option for patients with refractory cutaneous T‐cell lymphoma (CTCL) through replacement of the bone marrow responsible for lymphoma cells and possibly induction of a graft‐versus‐lymphoma effect. However, allo‐HSCT is not always curative; relapse of CTCL occurs in about half of patients post‐transplant...

article

Usage and safety of topical tacrolimus in patients with mycosis fungoides

David M. Weiner, Ashley K. Clark, Rahul S. Bhansali, Lisa Pappas‐Taffer, more

Clinical and Experimental Dermatology > 47 > 6 > 1200 - 1201

article

Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations

Daniel J. Lewis, Alain H. Rook

International Journal of Dermatology > 60 > 9 > e362 - e364

article

Pembrolizumab in mycosis fungoides and Sézary syndrome: Updated results of the CITN multicenter Phase 2 study

Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, Francine Foss, more

European Journal of Cancer > 2018 > 101 > S1 > S37

article

Gain of CD26 expression on the malignant T‐cells in relapsed erythrodermic leukemic mycosis fungoides

Filiberto Cedeno‐Laurent, Maria Wysocka, Amrom E. Obstfeld, Roberto A. Novoa, more

Journal of Cutaneous Pathology > 44 > 5 > 462 - 466

Loss of CD26 surface expression on the circulating malignant T‐cell is the most widely accepted diagnostic marker in patients with leukemic cutaneous T‐cell lymphoma (CTCL). CTCL cases with reemergence of CD7 and/or CD26 surface expression are unusual and of uncertain prognosis. We report the case of an erythrodermic leukemic mycosis fungoides patient who had achieved temporary remission after several...

article

CD164 identifies CD4⁺ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214

Bernice M. Benoit, Neha Jariwala, Geraldine O’Connor, Landon K. Oetjen, more

Archives of Dermatological Research > 2017 > 309 > 1 > 11-19

Sézary syndrome (SS), a leukemic variant of cutaneous T-cell lymphoma (CTCL), is associated with a significantly shorter life expectancy compared to skin-restricted mycosis fungoides. Early diagnosis of SS is, therefore, key to achieving enhanced therapeutic responses. However, the lack of a biomarker(s) highly specific for malignant CD4⁺ T cells in SS patients has been a serious obstacle in making...

article

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer

Marco Napoli, Avinashnarayan Venkatanarayan, Payal Raulji, Brooke A. Meyers, more

Cancer Cell > 2016 > 29 > 6 > 874-888

ΔNp63 is an oncogenic member of the p53 family and acts to inhibit the tumor-suppressive activities of the p53 family. By performing a chemical library screen, we identified histone deacetylase inhibitors (HDACi) as agents reducing ΔNp63 protein stability through the E3 ubiquitin ligase, Fbw7. ΔNp63 inhibition decreases the levels of its transcriptional target, DGCR8, and the maturation of let-7d...

article

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Filiberto Cedeno-Laurent, Elisha M. Singer, Maria Wysocka, Bernice M. Benoit, more

Clinical Immunology > 2015 > 158 > 1 > 1-7

Pruritus is one of the cardinal symptoms found in patients with leukemic cutaneous T cell lymphoma (CTCL). The nature of the pruritus experienced by CTCL patients is complex, involving different pathways and cell mediators, thus making it poorly responsive to conventional anti-itch therapies. Recent reports highlight the role of interleukin 31 (IL-31) as a novel cytokine involved in the pathogenesis...

article

Merkel cell polyomavirus in low levels in folliculotropic mycosis fungoides represents a passenger, not a driver

Rachel H. Gormley, Ellen J. Kim, Alain H. Rook, Carrie L. Kovarik, more

International Journal of Dermatology > 54 > 5 > e182 - e183

article

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Kenneth R. Carson, Scott D. Newsome, Ellen J. Kim, Nina D. Wagner‐Johnston, more

Cancer > 120 > 16 > 2464 - 2471

BACKGROUNDBrentuximab vedotin (BV) is an anti‐CD30 monoclonal antibody‐drug conjugate that was approved in 2011 for the treatment of patients with anaplastic large cell and Hodgkin lymphomas. The product label indicates that 3 patients who were treated with BV developed progressive multifocal leukoencephalopathy (PML), a frequently fatal JC virus‐induced central nervous system infection. Prior immunosuppressive...

article

Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy

Rachel S. Klein, James D. Dunlop, Sara S. Samimi, Kelly A. Morrissey, more

Journal of the American Academy of Dermatology > 2013 > 68 > 6 > 972-977

There is a paucity of effective therapies for patients with Sézary syndrome and advanced mycosis fungoides with peripheral blood involvement. Total skin electron beam (TSEB) radiation therapy is an extremely effective skin-directed therapy for these patients, but, until recently, it was thought not to signifcantly affect the peripheral blood malignant T-cell population.We conducted this study to determine...

article

Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children

Markus D. Boos, Sara S. Samimi, Alain H. Rook, Albert C. Yan, more

Current Dermatology Reports > 2013 > 2 > 4 > 203-211

Although more common with advanced age, the entire spectrum of benign and malignant cutaneous lymphoproliferative disorders can present in the pediatric population. Nevertheless, these conditions are often mistaken for other more common, benign dermatoses, resulting in delayed diagnosis. Standardized management of these conditions is also lacking. The purpose of this review is to provide an update...

article

Update on Epidemiology of Cutaneous T-Cell Lymphoma

Sara Samimi, Alain H. Rook, Ellen J. Kim

Current Dermatology Reports > 2013 > 2 > 1 > 35-41

Mycosis fungoides (MF) and Sézary syndrome (SS) comprise the majority of cutaneous T-cell lymphomas (CTCLs). Despite the rarity of these diseases, new insights into the epidemiology and pathophysiology of MF/SS are rapidly emerging that should lead to improved diagnosis and treatment. Here we discuss updates on MF/SS incidence, prognosis and survival, clinical variants, disease biomarkers, pathophysiology,...

article

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patients

Michael J. Kelly‐Sell, Youn H. Kim, Suzanne Straus, Bernice Benoit, more

American Journal of Hematology > 87 > 4 > 354 - 360

Romidepsin is the second histone deacetylase inhibitor (HDACi) approved for the treatment of advanced stages of cutaneous T‐cell lymphoma (CTCL). Recent in vitro data suggest that HDACis suppress immune function although these findings have not been confirmed in patients. Thus, we serially examined the cellular immune function of eight CTCL patients undergoing treatment with three cycles of romidepsin...

article

Peripheral blood findings in erythrodermic patients: Importance for the differential diagnosis of Sézary syndrome

Arielle R. Nagler, Sara Samimi, Andras Schaffer, Carmela C. Vittorio, more

Journal of the American Academy of Dermatology > 2012 > 66 > 3 > 503-508

Although Sézary syndrome (SS) represents an advanced stage of cutaneous T-cell lymphoma, this diagnosis presents a challenge even for the most experienced dermatologic clinicians. SS is characterized clinically by erythroderma, but can also be identified in the presence of specific histologic and peripheral blood findings. Erythrodermic cutaneous T-cell lymphoma can mimic a number of nonmalignant...

article

The relevance of photopheresis to autoreactive diseases

Sara Samimi, Alain H. Rook

Clinical Immunology > 2012 > 142 > 2 > 97-100

article

Inhibition of cell‐mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T‐cell lymphoma

Sasha Stephen, Kelly A. Morrissey, Bernice M. Benoit, Ellen J. Kim, more

American Journal of Hematology > 87 > 2 > 226 - 228

article

Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma

Brian A. Raphael, Kelly A. Morrissey, Ellen J. Kim, Carmela C. Vittorio, more

Journal of the American Academy of Dermatology > 2011 > 65 > 1 > 212-214

article

Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome

Katherine G. Evans, Andrea B. Troxel, Barbara J. DeNardo, Camille E. Introcaso, more

Journal of the American Academy of Dermatology > 2011 > 64 > 4 > 682-689

There is a need for standardized quantitative disease assessment measures in mycosis fungoides/Sézary syndrome. In 2005, a cutaneous T-cell lymphoma (CTCL)-severity index (SI) that not only measures disease extent (on a scale of 0-75) independent of the classic TNM(B) staging system but can also be used to estimate individual 5-year survival (SR5) was reported.We sought to assess the generalizability...

article

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Elise A. Olsen, Alain H. Rook, John Zic, Youn Kim, more

Journal of the American Academy of Dermatology > 2011 > 64 > 2 > 352-404

Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment...

Publication date

Last 3 years (2)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

INFONA - science communication portal

Search results for: Alain H. Rook

Management of relapsed cutaneous T‐Cell lymphoma following allogeneic hematopoietic stem cell transplantation: Review with representative patient case

Usage and safety of topical tacrolimus in patients with mycosis fungoides

Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations

Pembrolizumab in mycosis fungoides and Sézary syndrome: Updated results of the CITN multicenter Phase 2 study

Gain of CD26 expression on the malignant T‐cells in relapsed erythrodermic leukemic mycosis fungoides

CD164 identifies CD4⁺ T cells highly expressing genes associated with malignancy in Sézary syndrome: the Sézary signature genes, FCRL3, Tox, and miR-214

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer

Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities

Merkel cell polyomavirus in low levels in folliculotropic mycosis fungoides represents a passenger, not a driver

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project

Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy

Pityriasis Lichenoides and Cutaneous T Cell Lymphoma: An Update on the Diagnosis and Management of the Most Common Benign and Malignant Cutaneous Lymphoproliferative Diseases in Children

Update on Epidemiology of Cutaneous T-Cell Lymphoma

The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T‐cell lymphoma patients

Peripheral blood findings in erythrodermic patients: Importance for the differential diagnosis of Sézary syndrome

The relevance of photopheresis to autoreactive diseases

Inhibition of cell‐mediated immunity by the histone deacetylase inhibitor vorinostat: Implications for therapy of cutaneous T‐cell lymphoma

Psoralen plus ultraviolet A light may be associated with clearing of peripheral blood disease in advanced cutaneous T-cell lymphoma

Validity assessment of the cutaneous T-cell lymphoma severity index to predict prognosis in advanced mycosis fungoides/Sézary syndrome

Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)

Filter options

Publication date

Content availability

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Alain H. Rook

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Content availability

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options